November 18, 2026 12:17 PM
Biocon gets European Commission nod for breast cancer biosimilar Pebrilzo
Biopharmaceutical firm Biocon Ltd has received marketing authorisation from the European Commission (EC) for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer across multiple disease stages in the European Union. Biocon's per...




